Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07251998
PHASE2

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

172

Start Date

2025-12-22

Completion Date

2027-05

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

OTHER

ICP-332 Placebo Tablets

Placebo will be administered as tablet for 12 weeks

Locations (1)

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China